Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
2.660
+0.160 (6.40%)
Nov 25, 2025, 1:48 PM EST - Market open
PACB Revenue
Pacific Biosciences of California had revenue of $38.44M in the quarter ending September 30, 2025, a decrease of -3.82%. This brings the company's revenue in the last twelve months to $154.58M, down -10.72% year-over-year. In the year 2024, Pacific Biosciences of California had annual revenue of $154.01M, down -23.19%.
Revenue (ttm)
$154.58M
Revenue Growth
-10.72%
P/S Ratio
4.77
Revenue / Employee
$268,842
Employees
575
Market Cap
803.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 154.01M | -46.51M | -23.19% |
| Dec 31, 2023 | 200.52M | 72.22M | 56.29% |
| Dec 31, 2022 | 128.30M | -2.21M | -1.69% |
| Dec 31, 2021 | 130.51M | 51.62M | 65.43% |
| Dec 31, 2020 | 78.89M | -12.00M | -13.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PACB News
- 19 days ago - Pacific Biosciences of California, Inc. (PACB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes - GlobeNewsWire
- 21 days ago - PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China - GlobeNewsWire
- 4 weeks ago - PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 6 weeks ago - PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities - GlobeNewsWire
- 6 weeks ago - PacBio HiFi Technology Selected as Core Platform for South Korea's National Pangenome Project - GlobeNewsWire
- 6 weeks ago - Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic and Epigenetic Clues to Exceptional Longevity - GlobeNewsWire
- 7 weeks ago - PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs - GlobeNewsWire